<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006714</article-id><article-id pub-id-type="pmc">PMC11861164</article-id><article-id pub-id-type="doi">10.3390/vaccines13020167</article-id><article-id pub-id-type="publisher-id">vaccines-13-00167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Further Insights into the Measurement of Free Polysaccharide in Meningococcal Conjugate Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Beresford</surname><given-names>Nicola J.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="c1-vaccines-13-00167" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6556-1779</contrib-id><name><surname>De Benedetto</surname><given-names>Gianluigi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1314-5076</contrib-id><name><surname>Lockyer</surname><given-names>Kay</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6096-5339</contrib-id><name><surname>Gao</surname><given-names>Fang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role></contrib><contrib contrib-type="author"><name><surname>Burkin</surname><given-names>Karena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><name><surname>Lalwani</surname><given-names>Karan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9428-3536</contrib-id><name><surname>Bolgiano</surname><given-names>Barbara</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="c1-vaccines-13-00167" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Zeng</surname><given-names>Mingtao</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00167">Science, Research and Innovation Division, Medicines and Healthcare Products Regulatory Agency, South Mimms EN6 3QG, UK; <email>gianluigi.debenedetto@reithera.com</email> (G.D.B.); <email>kay.lockyer@mhra.gov.uk</email> (K.L.); <email>fang.gao@biojw.com</email> (F.G.); <email>k.lalwani01@gmail.com</email> (K.L.)</aff><author-notes><corresp id="c1-vaccines-13-00167"><label>*</label>Correspondence: <email>nicola.beresford@mhra.gov.uk</email> (N.J.B.); <email>barbara.bolgiano@gmail.com</email> (B.B.); Tel.: +44-7788-142424 (N.J.B.)</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>167</elocation-id><history><date date-type="received"><day>06</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Objectives</bold>: The purpose of this study was to further characterize the ultrafiltration (UF) method for determining free saccharide levels in glycoconjugate vaccines and compare it with other methods used for the determination of free saccharide levels in meningococcal glycoconjugate vaccines. <bold>Methods</bold>: We performed experiments on both meningococcal glycoconjugates and capsular polysaccharides, and compared UF, deoxycholate (DOC) precipitation, and solid-phase extraction (SPE) methods. Meningococcal capsular polysaccharides from groups A (MenA), C (MenC), and W (MenW) were depolymerized and characterized using SEC-MALS (size-exclusion chromatography with multi-angle laser light scattering) to determine the molecular weight and hydrodynamic size and then subjected to UF. The free saccharide content was quantified using HPAEC-PAD (high-performance anion-exchange chromatography with pulsed amperometric detection). <bold>Results</bold>: The characterization of size-reduced group C polysaccharide revealed weight-average molecular mass (Mw) ranging from 22,200 g/mol to 287,300 g/mol and hydrodynamic radii of 3.7 to 19.5 nm. Pore size studies confirmed that polysaccharides with diameters up to 15 nm filtered through the 100 kDa cellulose membrane. The smallest PS fragment tested (22,200 g/mol, 7.4 nm diameter) was partially recovered from the 30 kDa membrane. For MenC-CRM<sub>197</sub>, DOC yielded the lowest free saccharide content (&#x0003c;1%), UF gave moderate results (7&#x02013;8%), and SPE showed the highest and most variable values (up to 15%). For MenA- and MenW-CRM<sub>197</sub>, UF and DOC consistently provided low free saccharide levels (&#x0003c;2% and 3&#x02013;11%, respectively). <bold>Conclusions:</bold> The upper limits on the size of free group C meningococcal polysaccharides that can be ultrafiltered were assessed. Differences in the relative amount of free saccharide were observed between various methods used to control meningococcal conjugate vaccines.</p></abstract><kwd-group><kwd>CRM</kwd><kwd>filtration</kwd><kwd>glycoconjugate</kwd><kwd>HPAEC</kwd><kwd>HPLC</kwd><kwd>meningitis</kwd><kwd>meningococcal</kwd><kwd><italic toggle="yes">Neisseria meningitidis</italic></kwd><kwd>stability</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00167"><title>1. Introduction</title><p>The effectiveness of glycoconjugate vaccines in protecting against diseases caused by encapsulated bacteria depends on generating bactericidal antibodies specific to the polysaccharide (PS) constituting the bacterial capsule [<xref rid="B1-vaccines-13-00167" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00167" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00167" ref-type="bibr">3</xref>]. This requires preserving essential immunogenic saccharide&#x02013;protein epitopes, maintaining an optimal PS or oligosaccharide (OS) chain length, minimizing structural modifications, and securing efficient conjugation of PS or OS to a well-tolerated T-cell-dependent carrier protein [<xref rid="B4-vaccines-13-00167" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-13-00167" ref-type="bibr">5</xref>]. Certifying the stability and integrity of the conjugate in both the drug substance and the final product is one of the most critical elements [<xref rid="B6-vaccines-13-00167" ref-type="bibr">6</xref>]. The vaccine&#x02019;s potency is directly related to the effective amount of saccharide that is covalently attached to the carrier protein. Free saccharide, which is not bound to the protein, may remain as a residual from purification or may form due to PS instability as a result of hydrolysis or depolymerization. Only the conjugated saccharide is essential for clinical protection, and high levels of free saccharide result in a lower dose of conjugated saccharide and can also suppress the immune response. Therefore, each batch must be tested to ensure free saccharide levels remain within the specification limits during the manufacturing of upstream components to safeguard the vaccine&#x02019;s efficacy throughout its shelf life [<xref rid="B7-vaccines-13-00167" ref-type="bibr">7</xref>].</p><p>The analytical evaluation of vaccines is critical to determine consistent quality and immunogenicity. For glycoconjugates, this involves testing starting materials, intermediates, and the final conjugate [<xref rid="B8-vaccines-13-00167" ref-type="bibr">8</xref>]. It is important to measure free PS levels in both the bulk conjugate and the final product during release and throughout stability studies. Maintaining low free saccharide levels across the product&#x02019;s shelf life is critical for preserving vaccine potency. Stability-indicating tests are used to establish the relationship between vaccine quality, stability, and efficacy, and determine the product&#x02019;s expiration date.</p><p>The separation of free saccharide from conjugated saccharide is the first step in its determination, using techniques based on size, charge, protein hydrophobicity, or antigenic specificity. These include chromatographic techniques such as size-exclusion, ion-exchange [<xref rid="B9-vaccines-13-00167" ref-type="bibr">9</xref>], reverse-phase [<xref rid="B10-vaccines-13-00167" ref-type="bibr">10</xref>], and hydrophobic interaction. Other methods involve chemical precipitation of the conjugate with acid and/or detergents [<xref rid="B11-vaccines-13-00167" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00167" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00167" ref-type="bibr">13</xref>], ammonium sulfate or aluminum adsorption; capillary electrophoresis [<xref rid="B14-vaccines-13-00167" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00167" ref-type="bibr">15</xref>], centrifugal ultrafiltration (UF) [<xref rid="B16-vaccines-13-00167" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00167" ref-type="bibr">18</xref>], ultracentrifugation [<xref rid="B19-vaccines-13-00167" ref-type="bibr">19</xref>], solid-phase extraction (SPE) [<xref rid="B20-vaccines-13-00167" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00167" ref-type="bibr">21</xref>]; and antibody capture and immunoprecipitation [<xref rid="B22-vaccines-13-00167" ref-type="bibr">22</xref>]. Once separated, free saccharide is then quantified using chemical and immunological methods similar to those employed for measuring total saccharide content, including high-performance liquid chromatography (HPLC), high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) [<xref rid="B16-vaccines-13-00167" ref-type="bibr">16</xref>,<xref rid="B23-vaccines-13-00167" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-13-00167" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-13-00167" ref-type="bibr">25</xref>], gas chromatography (GC) after hydrolysis [<xref rid="B26-vaccines-13-00167" ref-type="bibr">26</xref>], colorimetric methods [<xref rid="B27-vaccines-13-00167" ref-type="bibr">27</xref>], and ELISA [<xref rid="B22-vaccines-13-00167" ref-type="bibr">22</xref>,<xref rid="B28-vaccines-13-00167" ref-type="bibr">28</xref>].</p><p>The ratio of free to total saccharide is a critical parameter for evaluating the effectiveness of the purification process and the integrity of the glycoconjugate. Validation of the chosen method is essential, especially given challenges such as electrostatic interactions and the diverse range of polysaccharides with respect to the carrier protein or conjugate. Forced degradation studies conducted during vaccine development can further confirm the method&#x02019;s suitability. Difficulties may occur when applying these methods to final formulations that contain stabilizing sugars or adjuvants, which can complicate the accurate measurement of specific saccharides. Combination vaccines with similar monosaccharide components present additional difficulties [<xref rid="B29-vaccines-13-00167" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00167" ref-type="bibr">30</xref>].</p><p>The ultrafiltration of proteins for the purpose of purification and characterization was developed on a commercial scale in the 1970s with Amicon Dia-Flo membranes, which were semipermeable membranes with different chemical characteristics that were used with external pressure or centrifugal force. Applications were later extended to polysaccharides and nucleic acids. Such size-based separations can also be applied to measure the unconjugated or &#x0201c;free&#x0201d; saccharide arising from small oligosaccharides or monosaccharides in a glycoconjugate vaccine [<xref rid="B16-vaccines-13-00167" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>].</p><p>In our laboratory, the level of free saccharide separated using a UF approach was shown to correlate with the serum bactericidal activity in meningococcal group A conjugate vaccines [<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>] and with vaccine immunogenicity in meningococcal groups A, C, W, X, and Y subjected to thermal stability studies [<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-13-00167" ref-type="bibr">32</xref>]. The objective of this study was to further characterize the ultrafiltration membrane method using sized PS fragments and to compare it with commonly used methods, such as detergent precipitation and hydrophobic bead binding, which rely on the hydrophobicity of the conjugated carrier protein. The effect of ionic strength on the free saccharide determination of MenC-CRM<sub>197</sub> (meningococcal group C&#x02013;cross-reacting material 197) [<xref rid="B33-vaccines-13-00167" ref-type="bibr">33</xref>] was also explored.</p></sec><sec id="sec2-vaccines-13-00167"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00167"><title>2.1. Polysaccharides</title><p>The source of the meningococcal group C PS was the 1st WHO International Standard (IS), NIBSC 08/214 [<xref rid="B34-vaccines-13-00167" ref-type="bibr">34</xref>]. Sized polysaccharides were prepared for the characterization of ultrafiltration membranes using mild acid hydrolysis, followed by purification via HPLC size-exclusion chromatography (HPLC-SEC).</p><p>The MenC PS (1 mg/mL) was depolymerized by incubation in 50 mM sodium acetate buffer (pH 4.7 &#x000b1; 0.05) at 73 &#x000b0;C &#x000b1; 2 &#x000b0;C for 15, 30, and 90 min, as described by Bardotti et al. [<xref rid="B35-vaccines-13-00167" ref-type="bibr">35</xref>]. Cooled samples were neutralized with an equivalent volume of 25 mM sodium hydroxide, vortexed, and stored at 4 &#x000b0;C before concentration and desalting using Pall Microsep Advance 3 kDa MWCO Omega centrifugal devices for 15 min at 4400&#x000d7; <italic toggle="yes">g</italic>. Retentates were washed three times with deionized water and freeze-dried overnight using a ModulyoD freeze dryer (Thermo Electron, Crawley, UK).</p><p>Lyophilized samples were dissolved in 0.22 &#x003bc;m filtered PBS &#x0201c;A&#x0201d; (10.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.84 mM KH<sub>2</sub>PO<sub>4</sub>, 171 mM NaCl, 3 mM KCl, pH 7.3&#x02013;7.5) and injected (approximately 800 &#x003bc;g) onto a Tosoh TSK PW<sub>XL</sub> guard column connected in series to a Tosoh TSKgel G4000 PW<sub>XL</sub> HPLC column using a Thermo Scientific Ultimate 3000 HPLC system (Dionex, Sunnyvale, CA, USA). The system was equipped with a multi-wavelength UV-Vis detector set at 214, 260, and 280 nm and a differential refractive index (dRI) detector (Knauer, Berlin, Germany) set at 35 &#x000b0;C. The autosampler was maintained at 4 &#x000b0;C, and the column compartment was set at 30 &#x000b0;C.</p><p>Samples were eluted at 0.250 mL/min with 0.22 &#x003bc;m filtered PBS &#x0201c;A&#x0201d; (60 min runtime). The void (V<sub>0</sub>) and total (V<sub>t</sub>) column volumes were determined using salmon DNA (Sigma Aldrich, St. Louis, MO, USA) and tyrosine (Sigma Aldrich), detected at 280 nm. Fractions were collected using the U3000 autosampler/fraction collector, collecting at 125 &#x003bc;L per fraction (30 s per fraction) into polypropylene autosampler vials and stored at &#x02212;20 &#x000b0;C before being pooled. Untreated (full-length, FL) MenC PS was also desalted as described above.</p><p>A purified PS with relatively smaller size dimensions (Mw 24,100 g/mol; RMS Rn 8.4 nm; Rh(v) 13.1 nm), designated as PS4 in Lockyer et al. [<xref rid="B36-vaccines-13-00167" ref-type="bibr">36</xref>], was used as a control in free saccharide assays.</p></sec><sec id="sec2dot2-vaccines-13-00167"><title>2.2. Glycoconjugate Vaccines</title><p>Six meningococcal-CRM<sub>197</sub> glycoconjugate preparations were sourced from a vaccine manufacturer and used to evaluate two different free saccharide separation methods. These included two lots of meningococcal group A OS (MenA) CRM<sub>197</sub> conjugate (designated A and B), two lots of meningococcal group C OS (MenC) CRM<sub>197</sub> conjugate (designated C and D), and two lots of meningococcal group W OS (MenW) CRM<sub>197</sub> conjugate (designated E and F).</p></sec><sec id="sec2dot3-vaccines-13-00167"><title>2.3. Saccharide Analysis</title><p>The MenC content of the PS and the MenA, MenC, or MenW content of the glycoconjugate samples were determined by HPAEC-PAD [<xref rid="B25-vaccines-13-00167" ref-type="bibr">25</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>] using the 1st WHO International Standards for MenA (NIBSC 13/246), MenC (NIBSC 08/214) [<xref rid="B34-vaccines-13-00167" ref-type="bibr">34</xref>], and MenW (NIBSC 16/152) polysaccharides (<uri xlink:href="https://nibsc.org/">https://nibsc.org/</uri>, accessed on 29 January 2025) [<xref rid="B25-vaccines-13-00167" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot4-vaccines-13-00167"><title>2.4. Characterization of the MenC Polysaccharide Fragments</title><p>The <italic toggle="yes">O</italic>-acetylation content of MenC PS was measured using NMR [<xref rid="B37-vaccines-13-00167" ref-type="bibr">37</xref>] and the micro-Hestrin colorimetric assay [<xref rid="B38-vaccines-13-00167" ref-type="bibr">38</xref>]. Sizing analysis by size-exclusion chromatography with multi-angle laser light scattering (SEC-MALS, Wyatt, Santa Barbara, CA, USA) was performed according to Lockyer et al. [<xref rid="B38-vaccines-13-00167" ref-type="bibr">38</xref>], using analytical HPLC columns in series: TSK guard, G6000 PW<sub>XL</sub>, and G5000 PW<sub>XL</sub>. The weight-average molecular mass (Mw, g/mol), polydispersity (Mw/Mn), and RMS radius moments (Rn, nm) values were determined, with a dn/dc value of 0.171 mL/g.</p></sec><sec id="sec2dot5-vaccines-13-00167"><title>2.5. Ultrafiltration for Free Saccharide Determination</title><p>To determine the % recovery of the sized polysaccharides through ultrafiltration membranes for the purpose of exploring the permeability of the membranes, samples were diluted to 20 &#x003bc;g saccharide/mL in dH<sub>2</sub>O or PBS &#x02018;A&#x02019;, pH 7.3&#x02013;7.5 buffer, and ultrafiltered using a pre-washed (three times with 0.5 mL dH<sub>2</sub>O, 10 min spin) Nanosep 3K Omega filter (PALL Life Science, Port Washington, NY, USA) or Microcon-10, -30, or -100 Ultracel YM-type regenerated cellulose filters (Millipore, Burlington, MA, USA) [<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>]. Ultrafiltration units containing samples were centrifuged at 7000&#x000d7; <italic toggle="yes">g</italic> for 15&#x02013;20 min at room temperature, and filtrates were analyzed using HPAEC-PAD (Thermo Scientific Dionex, Sunnyvale, CA, USA) [<xref rid="B25-vaccines-13-00167" ref-type="bibr">25</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>]. The sample for measuring the total saccharide (20 &#x003bc;g/mL) was not further filtered. Recovered and total polysaccharide samples were injected three and two times, respectively, and polysaccharide standards were run in triplicate, with two injections each. Percent recovery was calculated as the amount of saccharide in the filtrate divided by the amount of total saccharide in the sample. The % CV of MenC polysaccharide measured in different assays, based on percent recovery of the full-length IS from the filtrate, was 19% (30 kDa membrane) and 10% (with 100 kDa membrane) from four determinations with the 30 and 100 kDa membranes. The % CV of the total MenC saccharide in the IS was 4% from four different assays.</p><p>The UF method was also used for the purpose of testing whether an increase in ionic strength in the polysaccharide&#x02019;s solute would increase the permeation of unconjugated saccharide from a sample of glycoconjugate, measured in the free saccharide assay performed to measure vaccine integrity. One lot of a MenC-CRM<sub>197</sub> conjugate vaccine was filtered following dilution in water, or in 10 mM Bis-Tris, pH 7, containing 0, 5, 50, or 250 mM KCl, the buffer system used in the Zydney laboratory to study the effect of ionic strength [<xref rid="B39-vaccines-13-00167" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00167" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00167" ref-type="bibr">41</xref>]. In this case, free saccharide was separated from CRM<sub>197</sub> conjugate vaccines using Microcon-30 filters, pre-washed as above, and centrifuged at 7000&#x000d7; <italic toggle="yes">g</italic> for 20 min. Percent free saccharide was calculated as the amount of saccharide in the filtrate following filtration of the acid hydrolysate (0.1 M HCl at 80 &#x000b0;C for 2 h) [<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>] divided by the total saccharide in the sample. A % CV for free saccharide was calculated from three sample preparations (replicates) of filtered saccharide, divided by the average of two replicates of total saccharide, with 1&#x02013;9% intra-assay repeatability.</p><p>The final application of the UF method was performed for the purpose of comparing it with other methods for measuring free saccharide in a conjugate vaccine. Three serogroups of CRM<sub>197</sub> conjugates, MenA, MenC, and MenW, were evaluated as manufactured bulk conjugates (two bulks for each serogroup). Filtration was performed with the 30 kDa membrane as per [<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>] and HPAEC-PAD according to [<xref rid="B25-vaccines-13-00167" ref-type="bibr">25</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>]. Three replicates were injected twice, and two separate sessions were run. The % CV for repeatability was 0.1 (MenA), 0.65&#x02013;1.4 (MenC), and 0.1 (MenW).</p></sec><sec id="sec2dot6-vaccines-13-00167"><title>2.6. Deoxycholate (DOC) Precipitation for Free Saccharide Determination</title><p>To precipitate the meningococcal conjugate, the method was adapted from Lei et al. [<xref rid="B12-vaccines-13-00167" ref-type="bibr">12</xref>]. A total of 50 &#x003bc;L of freshly prepared 3% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) sodium deoxycholate (pH ~8.2) was mixed with 450 &#x003bc;L of the sample at a concentration of 20 &#x003bc;g saccharide/mL. The samples were vortexed and incubated on ice for 30 min. Next, 25 &#x003bc;L of 1 N HCl was added and the mixture was vortexed again and then centrifuged at 10,000&#x000d7; <italic toggle="yes">g</italic> for 30 min. The supernatant was removed and analyzed using HPAEC-PAD. In the same format as the UF method, % CV for repeatability was 0.1&#x02013;0.3 (MenA), 0.4 (MenC), and 0.6&#x02013;3.2 (MenW).</p></sec><sec id="sec2dot7-vaccines-13-00167"><title>2.7. Solid-Phase Extraction (SPE) for Free Saccharide Determination</title><p>To separate the free saccharide component of the meningococcal conjugate, samples were diluted to 5 &#x003bc;g saccharide/mL in dH<sub>2</sub>O. C4 columns (Grace-Vydac) were conditioned with methanol, washed with H<sub>2</sub>O, and equilibrated with 0.9% NaCl (pH 5.5) before sample addition. Free saccharides were eluted using NaCl solution and analyzed using HPAEC-PAD. The % CV for repeatability was 3.6&#x02013;9.0 (MenC).</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00167"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00167"><title>3.1. Ultrafiltration Membrane Permeability to Group C Meningococcal Polysaccharides</title><p>In our laboratory, Amicon YM-type regenerated cellulose ultrafiltration membranes are used to separate unconjugated saccharide from conjugated saccharide to determine the percentage of free saccharide in glycoconjugate vaccines [<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>]. These membranes are low-binding, anisotropic, hydrophilic, and made of regenerated cellulose, available in various pore sizes defined by nominal molecular weight cutoff values (NMWCO). These cutoff values, expressed in approximate kDa, indicate the membrane&#x02019;s ability to limit the permeability of proteins with the specified molecular weight. While this value is of use in selecting a membrane that will retain the conjugated carrier protein, such as CRM<sub>197</sub> or tetanus toxoid (TT), it is less helpful in understanding the size at which PS will permeate or be retained.</p><p>To further characterize the membranes for separating unconjugated PS, a panel of purified, sized MenC PS was prepared through mild acid hydrolysis to depolymerize full-length PS to varying extents. The size-exclusion chromatography (SEC) profiles following hydrolysis are shown in <xref rid="vaccines-13-00167-f001" ref-type="fig">Figure 1</xref>.</p><p>The chromatogram of the full-length (FL) MenC PS was consistent with that previously reported by Vipond et al. [<xref rid="B34-vaccines-13-00167" ref-type="bibr">34</xref>], showing a single main peak with a leading shoulder and later eluting peaks beginning at approximately 42 min. The three PS fragments from this FL PS were produced following acid hydrolysis treatment for 15, 30, and 90 min. All peaks eluted as a single main peak, with successively later eluting peaks producing insignificant RI and light scattering (90&#x000b0;) signals.</p><p>The <italic toggle="yes">O</italic>-acetylation of these fragments was equivalent to the full-length PS [<xref rid="B34-vaccines-13-00167" ref-type="bibr">34</xref>], with values of 69% (FL), 57% (15 min), 66% (30 min), and 68% (90 min) obtained by the micro-Hestrin method, which can underestimate the content. NMR-determined <italic toggle="yes">O</italic>-acetylation confirmed a value of 95% for the FL [<xref rid="B34-vaccines-13-00167" ref-type="bibr">34</xref>].</p><p>The size and purity of the full-length MenC PS and its fragments were determined using SEC-MALS, as shown in <xref rid="vaccines-13-00167-t001" ref-type="table">Table 1</xref>. The full-length PS had a Mw of 287,300 g/mol and a hydrodynamic radius of 19.5 nm, and there was a successive decrease in the Mw and radius with each successive fragment. Like the full-length PS, the 15 and 30 min samples were monodisperse, with a Mw/Mn of 1.0&#x02013;1.1. Only the smallest fragment showed higher polydispersity (1.5), perhaps reflecting the heterogeneity arising from the generation of depolymerized oligosaccharides under those conditions. Together, the panel comprised PS ranging from 22,2000 to 287,300 g/mol, with hydrodynamic radii of 3.7 to 19.5 nm.</p><p>This panel of polysaccharides was then tested for their recovery (or permeability) through ultrafiltration membranes with NMWCO values of 10 kDa, 30 kDa, and 100 kDa. <xref rid="vaccines-13-00167-f002" ref-type="fig">Figure 2</xref>a illustrates the recovery of the polysaccharides from the Microcon-10, -30, and -100 membranes. The full-length (287,300 g/mol) and 15 min (130,000 g/mol) MenC PS samples were largely retained by the 30 kDa and 100 kDa membranes. Neither the full-length nor the 30 min (52,800 g/mol) PS samples permeated through the 10 kDa membrane (<xref rid="vaccines-13-00167-f002" ref-type="fig">Figure 2</xref>a). The recovery of polysaccharides in the filtrates increased with larger pore sizes and smaller hydrodynamic volumes of the polysaccharides (<xref rid="vaccines-13-00167-f002" ref-type="fig">Figure 2</xref>a,b). The 3 kDa PES membrane retained the FL PS (<xref rid="vaccines-13-00167-f002" ref-type="fig">Figure 2</xref>b), with less than 1% recovery.</p><p>A separate study using atomic force microscopy determined the average pore sizes of these membrane types to be 8.7 nm for 3 kDa membranes, 11.3 nm for 10 kDa, 13.2 nm for 30 kDa, and 19.4 nm for 100 kDa membranes [<xref rid="B42-vaccines-13-00167" ref-type="bibr">42</xref>], with the range of sizes of pores extending to about &#x000b1;50% of the mean.</p><p>Based on these pore sizes alone, it would be expected that the full-length PS (of 38.8 nm diameter) should be retained by all the membranes tested (0% recovery), while the smallest fragment (7.4 nm diameter) would permeate the two larger pore size membranes of 30 and 100 kDa NMWCO. This expectation was confirmed experimentally. Only polysaccharides with a diameter under 15 nm were able to pass through the 100 kDa membrane (mean pore size of 19 nm). The smallest PS (22,200 g/mol, 7.4 nm diameter) was almost fully recovered from the 100 kDa membrane, and 45% recovered from the 30 kDa membrane (<xref rid="vaccines-13-00167-f002" ref-type="fig">Figure 2</xref>b).</p></sec><sec id="sec3dot2-vaccines-13-00167"><title>3.2. Effect of Ionic Strength on Free Saccharide Content Determined by Ultrafiltration</title><p>The free saccharide content of a MenC-CRM<sub>197</sub> conjugate lot, a measure of conjugate integrity, was determined after ultrafiltration on Microcon-30 centrifugal filters following dilution with varying ionic strength diluents. When the MenC-CRM<sub>197</sub> conjugate was diluted to 20 &#x000b5;g/mL total saccharide in H<sub>2</sub>O, the free saccharide content was 7.5%. Then, the conjugate was diluted to the same saccharide concentration using 10 mM Bis-Tris buffer, pH 7, with increasing ionic strength (KCl). As shown in <xref rid="vaccines-13-00167-t002" ref-type="table">Table 2</xref>, no appreciable differences in free saccharide quantification with increasing ionic strengths were observed under the experimental conditions, with results ranging from 6.2 to 6.8% free saccharide.</p></sec><sec id="sec3dot3-vaccines-13-00167"><title>3.3. Comparison of % Free Saccharide Determined by Ultrafiltration Compared with Detergent Precipitation and Hydrophobic Bead Methods</title><p>Three different methods for free saccharide analysis in glycoconjugate vaccines are widely used by vaccine manufacturers and quality control laboratories: UF, DOC, and SPE. Here, we evaluated these methods against the same MenC-CRM<sub>197</sub> conjugate lots. Detergent precipitation by DOC yielded the lowest reported free saccharide levels at &#x0003c;1% for both conjugated samples tested (<xref rid="vaccines-13-00167-t003" ref-type="table">Table 3</xref>). UF with 30 kDa filters showed a modest free saccharide content of 7&#x02013;8%, while the SPE method using C4 columns yielded significantly higher values of 15%. Good consistency was observed across replicates for both the UF and DOC methods, whereas the SPE method exhibited greater variability.</p><p>The low molecular weight (MW) MenC PS control (MenC 90 min) was a key component for distinguishing the differences between the methods. The almost full recovery (95%) of the PS in the supernatant of the control in the DOC method indicated that no PS is precipitated in the presence of the detergent. With the SPE method, approximately one-quarter of the material is lost during the extraction, indicating the interaction of the PS with the solid phase. The UF method applied to glycoconjugate vaccines showed a recovery of 20%, with the remaining being retained in the retentate of the filter. This indicates how the size of the PS fragment and the degradation pattern of glycoconjugate impact the overall result, with fragments of over 14 nm being retained by the filter.</p><p>The comparison between UF and DOC was further extended to other glycoconjugate groups, MenA-CRM<sub>197</sub> and MenW-CRM<sub>197</sub>. The UF method gave the lowest percent free saccharide recovery for the conjugated samples tested at &#x0003c;2% and slightly higher results for DOC (4% for MenA-CRM<sub>197</sub> samples and 3&#x02013;11% for MenW-CRM<sub>197</sub> samples) (<xref rid="vaccines-13-00167-t004" ref-type="table">Table 4</xref> and <xref rid="vaccines-13-00167-t005" ref-type="table">Table 5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00167"><title>4. Discussion</title><p>Glycoconjugate vaccines protect against diseases caused by encapsulated bacteria by generating bactericidal antibodies specific to the bacterial PS. Ensuring that the polysaccharide remains conjugated to the protein and that unconjugated or &#x0201c;free&#x0201d; saccharide levels are minimal is crucial for maintaining vaccine potency and immunogenicity [<xref rid="B43-vaccines-13-00167" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00167" ref-type="bibr">44</xref>]. Many methods have been explored for conjugate purification and analysis, including &#x0201c;free&#x0201d; saccharide separation and quantitation [<xref rid="B7-vaccines-13-00167" ref-type="bibr">7</xref>].</p><p>The methods employed for the separation and subsequent free saccharide quantitation depend on the nature of the protein conjugate and the PS [<xref rid="B7-vaccines-13-00167" ref-type="bibr">7</xref>], which in turn are reliant on their solution structure and behavior [<xref rid="B45-vaccines-13-00167" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00167" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00167" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00167" ref-type="bibr">48</xref>]. Indeed, different studies have emphasized the importance of the protein [<xref rid="B45-vaccines-13-00167" ref-type="bibr">45</xref>], while others emphasized the polysaccharide component [<xref rid="B41-vaccines-13-00167" ref-type="bibr">41</xref>,<xref rid="B46-vaccines-13-00167" ref-type="bibr">46</xref>] in dominating the solution behavior of the glycoconjugate. The PS chain (both native and chemically activated) can present a surface electrostatic charge and can be characterized by a range of molecular sizes (hydrodynamic volume and chain length), molecular masses (M<sub>w</sub>), and molecular dynamics. These factors, and the presence of substituent groups such as <italic toggle="yes">O</italic>-acetyl, may impact the shape, chemical nature, flexibility, and viscosity of PS solutions and can make physical separations more difficult, leading to challenges. In the case of the group C meningococcal PS, its relatively high flexibility [<xref rid="B46-vaccines-13-00167" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00167" ref-type="bibr">47</xref>,<xref rid="B49-vaccines-13-00167" ref-type="bibr">49</xref>] may facilitate more efficient transmission across ultrafiltration membranes relative to other serogroups.</p><p>The ultrafiltration method relies on the size-based separation of free <italic toggle="yes">saccharide</italic>, yet the membranes used for this type of separation are typically characterized by their ability to separate <italic toggle="yes">proteins</italic> of nominal sizes, for example, 10, 30, and 100 kDa. Their &#x0201c;cutoff&#x0201d; size values are used for selecting the most appropriate membranes to retain the carrier proteins (and conjugated saccharide) but are not informative in understanding the membrane retention or filterability of poly- or oligosaccharides. While it is essential that the selected membrane retains any conjugated carrier protein, for which the cutoff values are useful (for example, the choice of a 30 kDa membrane to retain the carrier protein CRM<sub>197</sub> (58.4 g/mol), and the choice of a 100 kDa membrane to retain tetanus toxoid (155&#x02013;163 g/mol) [<xref rid="B36-vaccines-13-00167" ref-type="bibr">36</xref>,<xref rid="B50-vaccines-13-00167" ref-type="bibr">50</xref>], a relatively large pore size for allowing for the filtration of unconjugated saccharide is generally desired.</p><p>The results obtained with the 30 kDa membrane suggest that the upper size limit of MenC PS that can pass through in a buffered solution is approximately 20,000 g/mol, whereas the upper PS size limit for the 100 kDa membrane was found to be approximately 53,000 g/mol (<xref rid="vaccines-13-00167-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-13-00167-f002" ref-type="fig">Figure 2</xref>a). These findings indicate that the method is ideally suited for determining the stability of glycoconjugate vaccines and performing lot control testing. Thus, the depolymerization and hydrolysis of end-of-chain groups releasing small oligosaccharides can be monitored, rather than measuring the content of large polysaccharides that remain unconjugated after manufacture, such as may occur in large TT conjugates that form cross-linked complexes. The relatively shorter chains typical of sun-type monomeric CRM<sub>197</sub> conjugates would be expected to pass through the filters. The UF method used in this study has been validated for evaluating the free saccharide in CRM<sub>197</sub> and TT conjugates when depolymerization leads to free saccharide impurities [<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-13-00167" ref-type="bibr">32</xref>]. Our results may also aid in the selection of membranes for filtering polysaccharides in a manufacturing setting when considering the adequacy of pore size, with further consideration of the ionic strength, PS charge, and flexibility.</p><p>Previous studies have investigated the effects of physical factors on the size and movement of charged bacterial polysaccharides through chromatography columns and ultrafiltration membranes and identified ionic strength as an important determinant for the purification and concentration of polysaccharides used for glycoconjugate vaccine production [<xref rid="B39-vaccines-13-00167" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00167" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00167" ref-type="bibr">41</xref>,<xref rid="B51-vaccines-13-00167" ref-type="bibr">51</xref>]. Specifically, PS transmission through an ultrafiltration membrane in dilute solutions decreased with decreasing ionic strength arising from the increase in the effective size of charged polysaccharides due to charge repulsion. Conversely, raising the ionic strength increased the transmission of the charged polysaccharides because of their smaller size arising from the shielding of intermolecular electrostatic interactions [<xref rid="B39-vaccines-13-00167" ref-type="bibr">39</xref>,<xref rid="B41-vaccines-13-00167" ref-type="bibr">41</xref>].</p><p>This can be used in two ways: a low solution ionic strength could be used to increase the retention of charged PS in a UF step used for PS concentration (where high retention is desired), while increased ionic strength could be used to enhance the removal of free (unconjugated/unreacted) PS in the preparation of conjugated vaccines. The starting concentration of PS in the UF module and the flow applied through the UF membrane could have an impact that is tightly interconnected with solution ionic strength and pH [<xref rid="B39-vaccines-13-00167" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00167" ref-type="bibr">40</xref>]. In addition, the nature of the membrane in terms of electrostatic and hydrophobic interactions with charged polysaccharides and proteins, as well as the surface charge of the membrane material itself, could have an impact on transmission through the membrane [<xref rid="B39-vaccines-13-00167" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00167" ref-type="bibr">40</xref>,<xref rid="B52-vaccines-13-00167" ref-type="bibr">52</xref>], the geometry of the UF module, and the flow rate applied through the membrane [<xref rid="B52-vaccines-13-00167" ref-type="bibr">52</xref>]. Membrane fouling due to PS or PS&#x02013;protein conjugate adsorption on the membrane or the formation of a gel layer can reduce UF efficiency due to a physical blockage of the pores. The adjustment of operating conditions, such as transmembrane pressure and crossflow velocity, can enhance UF performance by mitigating fouling and optimizing polarization effects and shear rates [<xref rid="B53-vaccines-13-00167" ref-type="bibr">53</xref>]. All these parameters that alter the PS conformation and interactions (both intramolecular and intermolecular, but also with the protein and the UF membrane) need to be considered in selecting the membrane and pore size of a UF membrane, in relation to the purpose of the UF step itself (retention vs. permeation), with the final aim of optimizing filtration processes in biotechnology.</p><p>The effect of solution conditions (pH and ionic strength) was also observed with size-exclusion chromatography of charged bacterial polysaccharides and their glycoconjugates [<xref rid="B41-vaccines-13-00167" ref-type="bibr">41</xref>]. Men A, C, W, X, and Y polysaccharides were previously shown to swell in water, relative to buffered solutions, with increases of greater than 10 nm hydrodynamic radii observed in water [<xref rid="B54-vaccines-13-00167" ref-type="bibr">54</xref>]. In this study, no difference was observed in the amount or recovery of free saccharide in a buffered solution due to increasing ionic strength up to 250 mM KCl or, conversely, when water was a diluent, probably due to residual salts present from the concentrated bulk conjugate. Deeper investigations are needed to better understand the role of the ionic strength on the behavior of bacterial polysaccharide solutions in both UF and SEC methodologies as applied to real-world manufacturing and analytical laboratory conditions. This study did not explore the impact of <italic toggle="yes">O</italic>-acetylation on the shape and flexibility of the polysaccharide, but the impacts of <italic toggle="yes">O</italic>-acetylation on conformation, viscosity, and filtration have been observed in groups A and C meningococcal and other saccharide types such as typhoid Vi [<xref rid="B54-vaccines-13-00167" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-13-00167" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-13-00167" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-13-00167" ref-type="bibr">57</xref>].</p><p>The ultrafiltration method has been validated for use in the control testing of various different saccharide types used in glycoconjugate vaccines, including Hib, meningococcal (A, C, W, X, Y), and typhoid polysaccharides, and results with a stability evaluation of the conjugates have shown its usefulness [<xref rid="B17-vaccines-13-00167" ref-type="bibr">17</xref>,<xref rid="B31-vaccines-13-00167" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-13-00167" ref-type="bibr">32</xref>]. This study focused on meningococcal group C, with additional analysis using groups A and W. Each of these has different charge densities, saccharide chain loading, flexibilities, and behavior [<xref rid="B46-vaccines-13-00167" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00167" ref-type="bibr">47</xref>], and this may be why relatively different levels of % free saccharide were measured by the various free saccharide methods compared in this study. MenC is one of the more flexible meningococcal serogroups [<xref rid="B46-vaccines-13-00167" ref-type="bibr">46</xref>], and it has been variously described as a flexible, random coil with a propensity to self-associate in high concentrations [<xref rid="B49-vaccines-13-00167" ref-type="bibr">49</xref>], or a zig-zag ribbon that &#x0201c;breathes&#x0201d; [<xref rid="B47-vaccines-13-00167" ref-type="bibr">47</xref>]. When the UF method was used, a higher percent of free MenC was found in the CRM<sub>197</sub>-conjugated vaccine studied here and in a separate MenC-CRM<sub>197</sub> conjugate in a pentavalent meningococcal vaccine [<xref rid="B32-vaccines-13-00167" ref-type="bibr">32</xref>] relative to other serogroups, yet the DOC precipitation method measured lower free MenC than the other serogroups. MenC glycoconjugates showed very different free saccharide percentages using the three methods used in this study (7&#x02013;8% for UF, less than 1% for DOC, and up to 15% for SPE, which yielded the highest variability).</p><p>Each of the free saccharide methods has advantages, drawbacks, and specific biases. Challenges with the free saccharide assay faced by one company are discussed in a review in this journal issue [<xref rid="B8-vaccines-13-00167" ref-type="bibr">8</xref>]. The UF method has limitations as a size-based method but is non-denaturing, and both free and total saccharide can be measured in the same assay.</p><p>The high recovery of the low MW polysaccharide control as demonstrated is an advantage of the detergent precipitation method, but the direct addition of acid and the need to keep samples cool during processing can be a drawback. Detergent precipitation is a relatively fast method but requires careful consideration of the carrier protein and the optimization of the pH and detergent concentration; additionally, it is important to assess whether the detergent interferes with saccharide quantification [<xref rid="B12-vaccines-13-00167" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00167" ref-type="bibr">13</xref>,<xref rid="B58-vaccines-13-00167" ref-type="bibr">58</xref>].</p><p>The C4 bead binding (or SPE) method, which relies on the hydrophobicity of the protein carrier, is one of the most complex of the methods and requires optimization for each of the serogroups and the carrier protein, with respect to the SPE column resin and conditioning procedure, to allow the free saccharide component to pass through the beads without binding whilst capturing the conjugated saccharide [<xref rid="B21-vaccines-13-00167" ref-type="bibr">21</xref>]. The hydrophobic beads or matrices of the SPE cartridges were a likely cause of the poorer recovery of the low MW MenC control in this study. The efficiency of the binding of the conjugated protein may, in theory, also lead to an overestimation of free saccharide relative to other methods.</p><p>Polysaccharides are generally considered to be hydrophilic molecules due to their solubility in aqueous solvents with favorable electrostatic interactions, and solvent complexation. The hydroxyl groups and ring oxygen atom on a saccharide unit of a PS can form hydrogen bonds with neighboring saccharide residues, resulting in intramolecular interactions; water also can serve as a hydrogen bond donor and acceptor and can compete with the intramolecular interactions and shield the PS from long-range electrostatic interactions [<xref rid="B45-vaccines-13-00167" ref-type="bibr">45</xref>]. However, under certain conditions, factors relating to higher PS concentrations, particular glycosidic linkages, and substituent groups; complexation of the negatively charged meningococcal polysaccharides with calcium or other divalent cations; the water hydration sphere and the presence of specific solutes and excipients; and the proximity of hydrophobic protein regions or nonpolar matrices may lead to the formation of local areas with polysaccharide hydrophobicity, which can lead to undesired solution behavior, insolubility, and irreversible binding to surfaces as observed with typhoid Vi polysaccharide [<xref rid="B8-vaccines-13-00167" ref-type="bibr">8</xref>]. The hydrophobic nature of PS, under these conditions, can also increase with chain length. The longer chain provides more surface area for potential hydrophobic interactions [<xref rid="B59-vaccines-13-00167" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-13-00167" ref-type="bibr">60</xref>]. The size and the length of the PS can have an impact on the binding and elution from the cartridge; enhanced binding of unconjugated longer chain polysaccharide to the SPE matrix together with the conjugate may occur, whereas smaller fragments may be more easily eluted.</p><p>With all of the methods, the conditions promoting the self-association of group C polysaccharide or association with the conjugate or other components should be avoided, and adequate ionic strength should be considered to improve solution behavior.</p><p>In 1997, during a WHO consultation on the requirements for the manufacturing and control of Hib vaccines, it was agreed that without a valid animal model for Hib conjugates, the most important measure of dose was the amount of &#x0201c;conjugated saccharide&#x0201d;. The recommendations for MenC conjugates state that &#x0201c;only the polysaccharide that is covalently bound to the carrier protein (i.e., conjugated polysaccharide) is immunologically important for clinical protection and excessive levels of unbound polysaccharide could potentially result in immunological hypo-responsiveness&#x0201d; [<xref rid="B44-vaccines-13-00167" ref-type="bibr">44</xref>]. Each batch of conjugate is therefore assessed for free and total saccharide. In evaluating glycoconjugate vaccines, the common approach is to determine both the free saccharide content and the total saccharide as separate fractions in order to determine the percentage of free saccharide. This has been further rationalized to evaluate the conjugated content, i.e., the effective dose. One approach has been to first remove the free saccharide element using a 30 kDa ultrafiltration membrane and subsequently recover and quantify the conjugated material from the retentate of the filter [<xref rid="B18-vaccines-13-00167" ref-type="bibr">18</xref>]. Consistency between the free saccharide analysis by SPE and ultrafiltration was confirmed for meningococcal group A [<xref rid="B18-vaccines-13-00167" ref-type="bibr">18</xref>]. Additional studies with such approaches to measure the &#x0201c;conjugated saccharide&#x0201d; are encouraged for products under development so that the glycoconjugate community can adopt a simpler and more direct measure of the dosage. Consideration of the use of other membrane materials, which may provide alternative pore sizes, such as with 50 kDa or larger pore size membranes and more selective pore sizes, could be helpful [<xref rid="B61-vaccines-13-00167" ref-type="bibr">61</xref>]. This study was a preliminary study, but it highlights the importance of understanding the polysaccharide size, shape, and solution behavior in improving methodologies for production and analysis. The eventual call to measure the &#x0201c;conjugated saccharide&#x0201d; will test the usefulness of the current methodology for new products.</p><p>Through further exploration of the size-dependent ultrafiltration method to determine the amount of &#x0201c;free&#x0201d; or unconjugated meningococcal saccharide present in glycoconjugate vaccines, the present study extends our knowledge of the significance of the hydrodynamic size of PS in relation to membrane pore size and represents, to our knowledge, the first study on the size characterization of meningococcal PS applied to filtration using regenerated cellulose (low binding) membranes. It serves to enhance our understanding of the role of this analytical approach and situates it with other methods to ensure the integrity and, ultimately, the potency of glycoconjugate vaccines.</p></sec></body><back><ack><title>Acknowledgments</title><p>B.B. would like to thank many generous friends and collaborators over the years for their contributions to her study in this interesting field of glycoconjugate vaccines.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, N.J.B., G.D.B., K.L. (Kay Lockyer), F.G. and B.B.; Methodology, all authors; Formal Analysis, all authors; Investigation, N.J.B., G.D.B., K.L. (Kay Lockyer), K.B. and K.L. (Karan Lalwani); Writing&#x02014;Original Draft Preparation, N.J.B., G.D.B. and B.B.; Writing&#x02014;Review and Editing, all authors; Supervision, N.J.B., F.G. and B.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The raw data supporting the conclusions of this article will be made available by the corresponding authors on request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00167"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avci</surname><given-names>F.</given-names></name>
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>Dull</surname><given-names>P.</given-names></name>
<name><surname>Hennessey</surname><given-names>J.</given-names></name>
<name><surname>Pavliak</surname><given-names>V.</given-names></name>
<name><surname>Prasad</surname><given-names>A.K.</given-names></name>
<name><surname>Vann</surname><given-names>W.</given-names></name>
<name><surname>Wacker</surname><given-names>M.</given-names></name>
<name><surname>Marcq</surname><given-names>O.</given-names></name>
</person-group><article-title>Glycoconjugates: What it would take to master these well-known yet little-understood immunogens for vaccine development</article-title><source>mSphere</source><year>2019</year><volume>4</volume><fpage>e00520-19</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00520-19</pub-id><pub-id pub-id-type="pmid">31554723</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00167"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>Micoli</surname><given-names>F.</given-names></name>
</person-group><article-title>Improving efficacy of glycoconjugate vaccines: From chemical conjugates to next generation constructs</article-title><source>Curr. Opin. Immunol.</source><year>2020</year><volume>65</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2020.03.015</pub-id><pub-id pub-id-type="pmid">32361591</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00167"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Biemans</surname><given-names>R.</given-names></name>
<name><surname>Micoli</surname><given-names>F.</given-names></name>
<name><surname>Romano</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Glycoconjugate vaccines, production and characterization</article-title><source>Recent Trends in Carbohydrate Chemistry: Synthesis, Structure and Function of Carbohydrates</source><person-group person-group-type="editor">
<name><surname>Rauter</surname><given-names>A.P.</given-names></name>
<name><surname>Christensen</surname><given-names>B.E.</given-names></name>
<name><surname>Soms&#x000e1;k</surname><given-names>L.</given-names></name>
<name><surname>Kosma</surname><given-names>P.</given-names></name>
<name><surname>Adamo</surname><given-names>R.</given-names></name>
</person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2020</year><volume>Volume 2</volume><comment>Chapter 8</comment><fpage>285</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-820954-7.00008-6</pub-id></element-citation></ref><ref id="B4-vaccines-13-00167"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>F.</given-names></name>
<name><surname>Jing</surname><given-names>X.B.</given-names></name>
<name><surname>Li</surname><given-names>Y.B.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>S.L.</given-names></name>
<name><surname>Yang</surname><given-names>Z.R.</given-names></name>
<name><surname>Feng</surname><given-names>S.</given-names></name>
</person-group><article-title>Optimization of the process for preparing bivalent polysaccharide conjugates to develop multivalent conjugate vaccines against <italic toggle="yes">Streptococcus pneumoniae</italic> or <italic toggle="yes">Neisseria meningitidis</italic> and comparison with the corresponding licensed vaccines in animal models</article-title><source>Curr. Med. Sci.</source><year>2023</year><volume>43</volume><fpage>22</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/s11596-022-2652-y</pub-id><pub-id pub-id-type="pmid">36680685</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00167"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Micoli</surname><given-names>F.</given-names></name>
<name><surname>Stefanetti</surname><given-names>G.</given-names></name>
<name><surname>MacLennan</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines</article-title><source>Front. Mol. Biosci.</source><year>2023</year><volume>10</volume><elocation-id>1201693</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2023.1201693</pub-id><pub-id pub-id-type="pmid">37261327</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00167"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Prasad</surname><given-names>A.K.</given-names></name>
<name><surname>Kim</surname><given-names>J.-H.</given-names></name>
<name><surname>Gu</surname><given-names>G.</given-names></name>
</person-group><article-title>Design and Development of Glycoconjugate Vaccines</article-title><source>Carbohydrate-Based Vaccines: From Concept to Clinic</source><person-group person-group-type="editor">
<name><surname>Prasad</surname><given-names>A.K.</given-names></name>
</person-group><series>ACS Symposium Series</series><publisher-name>American Chemical Society</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2018</year><comment>Chapter 4</comment><fpage>75</fpage><lpage>100</lpage></element-citation></ref><ref id="B7-vaccines-13-00167"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
<name><surname>Costantino</surname><given-names>P.</given-names></name>
<name><surname>Talaga</surname><given-names>P.</given-names></name>
<name><surname>Rodriguez</surname><given-names>R.</given-names></name>
<name><surname>Egan</surname><given-names>W.</given-names></name>
</person-group><article-title>Glycoconjugate Vaccines</article-title><source>Vaccine Analysis: Strategies, Principles, and Control</source><person-group person-group-type="editor">
<name><surname>Nunnally</surname><given-names>B.</given-names></name>
<name><surname>Turula</surname><given-names>V.</given-names></name>
<name><surname>Sitrin</surname><given-names>R.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2015</year><comment>Chapter 8</comment><fpage>301</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1007/978-3-662-45024-6_8</pub-id></element-citation></ref><ref id="B8-vaccines-13-00167"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Kale</surname><given-names>S.</given-names></name>
<name><surname>Phugare</surname><given-names>S.</given-names></name>
<name><surname>Goel</surname><given-names>S.K.</given-names></name>
<name><surname>Gairola</surname><given-names>S.</given-names></name>
</person-group><article-title>Analytical Challenges in Novel Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W, X)</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>1227</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12111227</pub-id><pub-id pub-id-type="pmid">39591130</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00167"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giannelli</surname><given-names>C.</given-names></name>
<name><surname>Cappelletti</surname><given-names>E.</given-names></name>
<name><surname>Di Benedetto</surname><given-names>R.</given-names></name>
<name><surname>Pippi</surname><given-names>F.</given-names></name>
<name><surname>Arcuri</surname><given-names>M.</given-names></name>
<name><surname>Di Cioccio</surname><given-names>V.</given-names></name>
<name><surname>Martin</surname><given-names>L.B.</given-names></name>
<name><surname>Saul</surname><given-names>A.</given-names></name>
<name><surname>Micoli</surname><given-names>F.</given-names></name>
</person-group><article-title>Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever</article-title><source>J. Pharm. Biomed. Anal.</source><year>2017</year><volume>139</volume><fpage>143</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2017.02.042</pub-id><pub-id pub-id-type="pmid">28282600</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00167"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schuchmann</surname><given-names>D.C.</given-names></name>
<name><surname>Hou</surname><given-names>W.</given-names></name>
<name><surname>Creahan</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Jones</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Sensitive quantitation of low level free polysaccharide in conjugate vaccines by size exclusion chromatography-reverse phase liquid chromatography with UV detection</article-title><source>J. Pharm. Biomed. Anal.</source><year>2020</year><volume>180</volume><elocation-id>113043</elocation-id><pub-id pub-id-type="doi">10.1016/j.jpba.2019.113043</pub-id><pub-id pub-id-type="pmid">31864110</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00167"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>Y.Y.</given-names></name>
<name><surname>Anderson</surname><given-names>R.</given-names></name>
<name><surname>McIver</surname><given-names>J.</given-names></name>
<name><surname>Gupta</surname><given-names>R.K.</given-names></name>
<name><surname>Siber</surname><given-names>G.R.</given-names></name>
</person-group><article-title>A simple and rapid method for measuring unconjugated capsular polysaccharide (PRP) of <italic toggle="yes">Haemophilus influenzae</italic> type b in PRP-tetanus toxoid conjugate vaccine</article-title><source>Biologicals</source><year>1998</year><volume>26</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1006/biol.1997.0121</pub-id><pub-id pub-id-type="pmid">9637747</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00167"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>Q.P.</given-names></name>
<name><surname>Shannon</surname><given-names>A.G.</given-names></name>
<name><surname>Heller</surname><given-names>R.K.</given-names></name>
<name><surname>Lamb</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines</article-title><source>Dev. Biol.</source><year>2000</year><volume>103</volume><fpage>259</fpage><lpage>264</lpage></element-citation></ref><ref id="B13-vaccines-13-00167"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>Q.P.</given-names></name>
<name><surname>Lamb</surname><given-names>D.H.</given-names></name>
<name><surname>Heller</surname><given-names>R.</given-names></name>
<name><surname>Pietrobon</surname><given-names>P.</given-names></name>
</person-group><article-title>Quantitation of low level unconjugated polysaccharide in tetanus toxoid-conjugate vaccine by HPAEC/PAD following rapid separation by deoxycholate/HCl</article-title><source>J. Pharm. Biomed. Anal.</source><year>2000</year><volume>6</volume><fpage>1087</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/S0731-7085(99)00183-1</pub-id></element-citation></ref><ref id="B14-vaccines-13-00167"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamb</surname><given-names>D.H.</given-names></name>
<name><surname>Lei</surname><given-names>Q.P.</given-names></name>
<name><surname>Hakim</surname><given-names>N.</given-names></name>
<name><surname>Rizzo</surname><given-names>S.</given-names></name>
<name><surname>Cash</surname><given-names>P.</given-names></name>
</person-group><article-title>Determination of meningococcal polysaccharides by capillary zone electrophoresis</article-title><source>Anal. Biochem.</source><year>2005</year><volume>338</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2004.12.002</pub-id><pub-id pub-id-type="pmid">15745746</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00167"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.-M.</given-names></name>
<name><surname>Petermann</surname><given-names>R.</given-names></name>
<name><surname>Porte</surname><given-names>Q.</given-names></name>
<name><surname>Berezuk</surname><given-names>G.</given-names></name>
<name><surname>Crowe</surname><given-names>B.</given-names></name>
<name><surname>Shirtz</surname><given-names>J.</given-names></name>
</person-group><article-title>Long-term thermal stability of group C meningococcal polysaccharide&#x02013;Tetanus toxoid conjugate vaccine</article-title><source>Hum. Vaccine</source><year>2007</year><volume>3</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.4161/hv.3.1.3749</pub-id><pub-id pub-id-type="pmid">17264684</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00167"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bardotti</surname><given-names>A.</given-names></name>
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
<name><surname>Ricci</surname><given-names>S.</given-names></name>
<name><surname>D&#x02019;Ascenzi</surname><given-names>S.</given-names></name>
<name><surname>Guarnieri</surname><given-names>V.</given-names></name>
<name><surname>Averani</surname><given-names>G.</given-names></name>
<name><surname>Constantino</surname><given-names>P.</given-names></name>
</person-group><article-title>Quantitative determination of saccharide in Haemophilus influenzae type b glycoconjugate vaccines, alone and in combination with DPT, by use of high-performance anion-exchange chromatography with pulsed amperometric detection</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>1982</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00535-6</pub-id><pub-id pub-id-type="pmid">10706959</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00167"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>M.M.</given-names></name>
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
<name><surname>Corbel</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM<sub>197</sub> conjugate vaccines</article-title><source>Vaccine</source><year>2000</year><volume>19</volume><fpage>716</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00261-9</pub-id><pub-id pub-id-type="pmid">11115692</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00167"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rech</surname><given-names>F.</given-names></name>
<name><surname>De Ricco</surname><given-names>R.</given-names></name>
<name><surname>Giannini</surname><given-names>S.</given-names></name>
<name><surname>Nompari</surname><given-names>L.</given-names></name>
<name><surname>Paludi</surname><given-names>M.</given-names></name>
<name><surname>Berti</surname><given-names>S.</given-names></name>
<name><surname>Parlati</surname><given-names>C.</given-names></name>
<name><surname>Cianetti</surname><given-names>S.</given-names></name>
<name><surname>Berti</surname><given-names>F.</given-names></name>
</person-group><article-title>Glycoconjugate content quantification to assess vaccine potency: A simplified approach</article-title><source>Biologicals</source><year>2022</year><volume>76</volume><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2022.02.004</pub-id><pub-id pub-id-type="pmid">35264299</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00167"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Belfast</surname><given-names>M.</given-names></name>
<name><surname>Lu</surname><given-names>R.</given-names></name>
<name><surname>Capen</surname><given-names>R.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.A.</given-names></name>
<name><surname>Gimenez</surname><given-names>J.</given-names></name>
<name><surname>Sitrin</surname><given-names>R.</given-names></name>
<name><surname>Mancinelli</surname><given-names>R.</given-names></name>
</person-group><article-title>A practical approach to optimization and validation of a HPLC assay for analysis of polyribosylribitol phosphate in complex combination vaccines</article-title><source>J. Chromatogr. B</source><year>2006</year><volume>832</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2005.12.053</pub-id></element-citation></ref><ref id="B20-vaccines-13-00167"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosskopf</surname><given-names>U.</given-names></name>
<name><surname>Daas</surname><given-names>A.</given-names></name>
<name><surname>Terao</surname><given-names>E.</given-names></name>
<name><surname>von Hunolstein</surname><given-names>C.</given-names></name>
</person-group><article-title>Collaborative study on saccharide quantification of the <italic toggle="yes">Haemophilus influenzae</italic> type b component in liquid vaccine presentations</article-title><source>Pharmeur. Bio. Sci. Notes</source><year>2017</year><volume>2017</volume><fpage>44</fpage><lpage>68</lpage></element-citation></ref><ref id="B21-vaccines-13-00167"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Ricco</surname><given-names>R.</given-names></name>
<name><surname>Rech</surname><given-names>F.</given-names></name>
<name><surname>Onnis</surname><given-names>V.</given-names></name>
<name><surname>Sanna Coccone</surname><given-names>S.</given-names></name>
<name><surname>Scalia</surname><given-names>G.</given-names></name>
<name><surname>Marcozzi</surname><given-names>C.</given-names></name>
<name><surname>Gavini</surname><given-names>M.</given-names></name>
<name><surname>Beni</surname><given-names>S.</given-names></name>
<name><surname>Giannini</surname><given-names>S.</given-names></name>
<name><surname>Nompari</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Development of a new solid-phase extraction base method for free saccharide content estimation of meningococcal conjugate vaccines</article-title><source>ACS Omega</source><year>2022</year><volume>7</volume><fpage>39875</fpage><lpage>39883</lpage><pub-id pub-id-type="doi">10.1021/acsomega.2c04013</pub-id><pub-id pub-id-type="pmid">36385865</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00167"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grozdanovic</surname><given-names>M.</given-names></name>
<name><surname>Samuel</surname><given-names>R.</given-names></name>
<name><surname>Grau</surname><given-names>B.</given-names></name>
<name><surname>Ansbro</surname><given-names>F.</given-names></name>
</person-group><article-title>Serotype-specific quantification of residual free polysaccharide in multivalent pneumococcal conjugate vaccines</article-title><source>Glycoconj. J.</source><year>2024</year><volume>41</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1007/s10719-023-10143-6</pub-id><pub-id pub-id-type="pmid">38224414</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00167"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ricci</surname><given-names>S.</given-names></name>
<name><surname>Bardotti</surname><given-names>A.</given-names></name>
<name><surname>D&#x02019;Ascenzi</surname><given-names>S.</given-names></name>
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
</person-group><article-title>Development of a new method for the quantitative analysis of the extracellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>1989</fpage><lpage>1997</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00427-8</pub-id><pub-id pub-id-type="pmid">11228369</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00167"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cook</surname><given-names>M.C.</given-names></name>
<name><surname>Bliu</surname><given-names>A.</given-names></name>
<name><surname>Kunkel</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: Optimisation of hydrolysis conditions and chromatographic methods</article-title><source>Vaccine</source><year>2013</year><volume>12</volume><fpage>3702</fpage><lpage>3711</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.098</pub-id><pub-id pub-id-type="pmid">23764533</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00167"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Beresford</surname><given-names>N.</given-names></name>
<name><surname>Lockyer</surname><given-names>K.</given-names></name>
<name><surname>Burkin</surname><given-names>K.</given-names></name>
<name><surname>Rigsby</surname><given-names>P.</given-names></name>
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
</person-group><article-title>Saccharide dosage content of meningococcal polysaccharide conjugate vaccines determined using WHO International Standards for serogroup A, C, W, Y and X polysaccharides</article-title><source>Biologicals</source><year>2021</year><volume>70</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2021.01.001</pub-id><pub-id pub-id-type="pmid">33518432</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00167"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
<name><surname>Laskowich</surname><given-names>E.R.</given-names></name>
<name><surname>Arumugham</surname><given-names>R.G.</given-names></name>
<name><surname>Kaiser</surname><given-names>R.E.</given-names></name>
<name><surname>MacMichael</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Determination of saccharide content in pneumococcal polysaccharides and conjugate vaccines by GC-MSD</article-title><source>Anal. Biochem.</source><year>2005</year><volume>347</volume><fpage>262</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2005.09.022</pub-id><pub-id pub-id-type="pmid">16266683</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00167"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Zablackis</surname><given-names>E.</given-names></name>
<name><surname>Talaga</surname><given-names>P.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
</person-group><article-title>Bacterial Polysaccharide Vaccines: Analytical Perspectives</article-title><source>Vaccine Analysis: Strategies, Principles, and Control</source><person-group person-group-type="editor">
<name><surname>Nunnally</surname><given-names>B.</given-names></name>
<name><surname>Turula</surname><given-names>V.</given-names></name>
<name><surname>Sitrin</surname><given-names>R.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2015</year><comment>Chapter 7</comment><fpage>271</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1007/978-3-662-45024-6_7</pub-id></element-citation></ref><ref id="B28-vaccines-13-00167"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saydam</surname><given-names>M.</given-names></name>
<name><surname>Rigsby</surname><given-names>P.</given-names></name>
<name><surname>Mawas</surname><given-names>F.</given-names></name>
</person-group><article-title>A novel enzyme-linked immuno-sorbent assay (ELISA) for the quantification of total and free polysaccharide in Haemophilus influenzae b-Tetanus toxoid conjugate vaccines in monovalent and combined vaccine formulations</article-title><source>Biologicals</source><year>2014</year><volume>42</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2013.10.002</pub-id><pub-id pub-id-type="pmid">24200313</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00167"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whang</surname><given-names>Y.H.</given-names></name>
<name><surname>Kim</surname><given-names>S.K.</given-names></name>
<name><surname>Yoon</surname><given-names>H.</given-names></name>
<name><surname>Choi</surname><given-names>S.K.</given-names></name>
<name><surname>Baik</surname><given-names>Y.O.</given-names></name>
<name><surname>Lee</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>I.</given-names></name>
</person-group><article-title>Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0243909</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0243909</pub-id><pub-id pub-id-type="pmid">33301525</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00167"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deng</surname><given-names>J.Z.</given-names></name>
<name><surname>Kuster</surname><given-names>N.</given-names></name>
<name><surname>Drumheller</surname><given-names>A.</given-names></name>
<name><surname>Lin</surname><given-names>M.</given-names></name>
<name><surname>Ansbro</surname><given-names>F.</given-names></name>
<name><surname>Grozdanovic</surname><given-names>M.</given-names></name>
<name><surname>Samuel</surname><given-names>R.</given-names></name>
<name><surname>Zhuang</surname><given-names>P.</given-names></name>
</person-group><article-title>Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00584-9</pub-id><pub-id pub-id-type="pmid">36690697</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00167"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beresford</surname><given-names>N.J.</given-names></name>
<name><surname>Martino</surname><given-names>A.</given-names></name>
<name><surname>Feavers</surname><given-names>I.M.</given-names></name>
<name><surname>Corbel</surname><given-names>M.J.</given-names></name>
<name><surname>Bai</surname><given-names>X.</given-names></name>
<name><surname>Borrow</surname><given-names>R.</given-names></name>
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
</person-group><article-title>Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM<sub>197</sub>, DT and TT glycoconjugate vaccines</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>3598</fpage><lpage>3606</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.066</pub-id><pub-id pub-id-type="pmid">28408122</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00167"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
<name><surname>Moran</surname><given-names>E.</given-names></name>
<name><surname>Beresford</surname><given-names>N.J.</given-names></name>
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Care</surname><given-names>R.</given-names></name>
<name><surname>Desai</surname><given-names>T.</given-names></name>
<name><surname>Nordgren</surname><given-names>I.K.</given-names></name>
<name><surname>Rudd</surname><given-names>T.R.</given-names></name>
<name><surname>Feavers</surname><given-names>I.M.</given-names></name>
<name><surname>Bore</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global Use</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>928</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10080928</pub-id><pub-id pub-id-type="pmid">34451392</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00167"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giannini</surname><given-names>G.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>Ratti</surname><given-names>G.</given-names></name>
</person-group><article-title>The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197</article-title><source>Nucleic Acids Res.</source><year>1984</year><volume>12</volume><fpage>4063</fpage><lpage>4069</lpage><pub-id pub-id-type="doi">10.1093/nar/12.10.4063</pub-id><pub-id pub-id-type="pmid">6427753</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00167"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vipond</surname><given-names>C.</given-names></name>
<name><surname>Mulloy</surname><given-names>B.</given-names></name>
<name><surname>Rigsby</surname><given-names>P.</given-names></name>
<name><surname>Burkin</surname><given-names>K.</given-names></name>
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
<collab>MenC IS Working Group</collab>
</person-group><article-title>Evaluation of a candidate International Standard for Meningococcal Group C polysaccharide</article-title><source>Biologicals</source><year>2012</year><volume>40</volume><fpage>353</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2012.03.003</pub-id><pub-id pub-id-type="pmid">22622331</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00167"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bardotti</surname><given-names>A.</given-names></name>
<name><surname>Averani</surname><given-names>G.</given-names></name>
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>Berti</surname><given-names>S.</given-names></name>
<name><surname>Galli</surname><given-names>C.</given-names></name>
<name><surname>Giannini</surname><given-names>S.</given-names></name>
<name><surname>Fabbri</surname><given-names>B.</given-names></name>
<name><surname>Proietti</surname><given-names>D.</given-names></name>
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
<name><surname>Ricci</surname><given-names>S.</given-names></name>
</person-group><article-title>Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against <italic toggle="yes">Neisseria meningitidis</italic> groups Y and W135</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1887</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.10.021</pub-id><pub-id pub-id-type="pmid">15734061</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00167"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lockyer</surname><given-names>K.</given-names></name>
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Francis</surname><given-names>R.J.</given-names></name>
<name><surname>Eastwood</surname><given-names>D.</given-names></name>
<name><surname>Khatri</surname><given-names>B.</given-names></name>
<name><surname>Stebbings</surname><given-names>R.</given-names></name>
<name><surname>Derrick</surname><given-names>J.P.</given-names></name>
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
</person-group><article-title>Higher mass meningococcal group C-tetanus toxoid vaccines conjugated with carbodiimide correlate with greater immunogenicity</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>2859</fpage><lpage>2869</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.02.012</pub-id><pub-id pub-id-type="pmid">32089463</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00167"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lemercinier</surname><given-names>X.</given-names></name>
<name><surname>Jones</surname><given-names>C.</given-names></name>
</person-group><article-title>Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from <italic toggle="yes">Neisseria meningitidis</italic> used in vaccine production</article-title><source>Carbohydr. Res.</source><year>1996</year><volume>296</volume><fpage>83</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0008-6215(96)00253-4</pub-id><pub-id pub-id-type="pmid">9008844</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00167"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Lockyer</surname><given-names>K.</given-names></name>
<name><surname>Logan</surname><given-names>A.</given-names></name>
<name><surname>Davis</surname><given-names>S.</given-names></name>
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
<name><surname>Rijpkema</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>G.</given-names></name>
<name><surname>Prasad</surname><given-names>S.D.</given-names></name>
<name><surname>Dondapati</surname><given-names>S.P.</given-names></name>
<name><surname>Sounkhla</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Evidence of extended thermo-stability of typhoid polysaccharide conjugate vaccines</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><elocation-id>1707</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9081707</pub-id><pub-id pub-id-type="pmid">34442786</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00167"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadidi</surname><given-names>M.</given-names></name>
<name><surname>Buckley</surname><given-names>J.J.</given-names></name>
<name><surname>Zydney</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Ultrafiltration behavior of bacterial polysaccharides used in vaccines</article-title><source>J. Membr. Sci.</source><year>2015</year><volume>490</volume><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.memsci.2015.04.047</pub-id></element-citation></ref><ref id="B40-vaccines-13-00167"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadidi</surname><given-names>M.</given-names></name>
<name><surname>Buckley</surname><given-names>J.J.</given-names></name>
<name><surname>Zydney</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Effect of electrostatic interactions on the ultrafiltation behavior of charged bacterial capsular polysaccharides</article-title><source>Biotechnol. Prog.</source><year>2016</year><volume>32</volume><fpage>1531</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1002/btpr.2367</pub-id><pub-id pub-id-type="pmid">27673326</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00167"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadidi</surname><given-names>M.</given-names></name>
<name><surname>Buckley</surname><given-names>J.J.</given-names></name>
<name><surname>Zydney</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Effects of solution conditions on characteristics and size exclusion chromatography of pneumococcal PSs and conjugate vaccines</article-title><source>Carbohydr. Polym.</source><year>2016</year><volume>152</volume><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2016.06.095</pub-id><pub-id pub-id-type="pmid">27516244</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00167"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bowen</surname><given-names>R.W.</given-names></name>
<name><surname>Hilal</surname><given-names>N.</given-names></name>
<name><surname>Lovitt</surname><given-names>R.W.</given-names></name>
<name><surname>Williams</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Atomic force microscope studies of membranes: Surface pore structures of Diaflo ultrafiltration membranes</article-title><source>J. Colloid Interface Sci.</source><year>1996</year><volume>180</volume><fpage>350</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1006/jcis.1996.0313</pub-id></element-citation></ref><ref id="B43-vaccines-13-00167"><label>43.</label><element-citation publication-type="book"><article-title>Recommendations to Assure the Quality, Safety and Efficacy of Group A Meningococcal Conjugate Vaccines</article-title><source>Annex 2. WHO Technical Report Series-Number 962</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2011</year><fpage>115</fpage><lpage>171</lpage><comment>Available online: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/44678/WHO_TRS_962_eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/44678/WHO_TRS_962_eng.pdf?sequence=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-29">(accessed on 29 January 2025)</date-in-citation></element-citation></ref><ref id="B44-vaccines-13-00167"><label>44.</label><element-citation publication-type="book"><article-title>Recommendations for the Production and Control of Meningococcal Group C Conjugate Vaccines</article-title><source>Annex 2. WHO Technical Report Series-Number 924</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2004</year><fpage>102</fpage><lpage>128</lpage><comment>Available online: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/42921/WHO_TRS_924.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/42921/WHO_TRS_924.pdf?sequence=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-29">(accessed on 29 January 2025)</date-in-citation></element-citation></ref><ref id="B45-vaccines-13-00167"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>Costantino</surname><given-names>P.</given-names></name>
<name><surname>Fragai</surname><given-names>M.</given-names></name>
<name><surname>Luchinat.</surname></name>
</person-group><article-title>Water accessibility, aggregation, and motional features of polysaccharide-protein conjugate vaccines</article-title><source>Biophys. J.</source><year>2004</year><volume>86</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(04)74078-3</pub-id><pub-id pub-id-type="pmid">14695244</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00167"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelhameed</surname><given-names>A.</given-names></name>
<name><surname>Morris</surname><given-names>G.</given-names></name>
<name><surname>Almutairi</surname><given-names>F.</given-names></name>
<name><surname>Adams</surname><given-names>G.G.</given-names></name>
<name><surname>Duvivier</surname><given-names>P.</given-names></name>
<name><surname>Conrath</surname><given-names>K.</given-names></name>
<name><surname>Harding</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Solution conformation and flexibility of capsular polysaccharides from <italic toggle="yes">Neisseria meningitidis</italic> and glycoconjugates with the tetanus toxoid protein</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>35588</elocation-id><pub-id pub-id-type="doi">10.1038/srep35588</pub-id><pub-id pub-id-type="pmid">27782149</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00167"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuttel</surname><given-names>M.M.</given-names></name>
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
</person-group><article-title>Molecular modeling provides insights into the loading of sialic acid- containing antigens onto CRM<sub>197</sub>: The role of chain flexibility in conjugation efficiency and glycoconjugate architecture</article-title><source>Glycoconj. J.</source><year>2021</year><volume>38</volume><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/s10719-021-09991-x</pub-id><pub-id pub-id-type="pmid">33721150</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00167"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malito</surname><given-names>E.</given-names></name>
<name><surname>Bursulaya</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Lo Surdo</surname><given-names>P.</given-names></name>
<name><surname>Picchianti</surname><given-names>M.</given-names></name>
<name><surname>Balducci</surname><given-names>E.</given-names></name>
<name><surname>Biancucci</surname><given-names>M.</given-names></name>
<name><surname>Brock</surname><given-names>A.</given-names></name>
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>Bottomley</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>5229</fpage><lpage>5234</lpage><pub-id pub-id-type="doi">10.1073/pnas.1201964109</pub-id><pub-id pub-id-type="pmid">22431623</pub-id>
</element-citation></ref><ref id="B49-vaccines-13-00167"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsunashima</surname><given-names>Y.</given-names></name>
<name><surname>Moro</surname><given-names>K.</given-names></name>
<name><surname>Chu</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>T.Y.</given-names></name>
</person-group><article-title>Characterization of group C meningococcal polysaccharide by light-scattering spectroscopy. III. Determination of molecular weight, radius of gyration, and translational diffusional coefficient</article-title><source>Biopolymers</source><year>1978</year><volume>17</volume><fpage>251</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/bip.1978.360170202</pub-id><pub-id pub-id-type="pmid">416859</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00167"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jumel</surname><given-names>K.</given-names></name>
<name><surname>Ho</surname><given-names>M.M.</given-names></name>
<name><surname>Bolgiano</surname><given-names>B.</given-names></name>
</person-group><article-title>Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography/multi-angle laser light scattering. Biotechnol</article-title><source>Appl. Biochem.</source><year>2002</year><volume>36</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1042/BA20020066</pub-id><pub-id pub-id-type="pmid">12452806</pub-id>
</element-citation></ref><ref id="B51-vaccines-13-00167"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emami</surname><given-names>P.</given-names></name>
<name><surname>Motevalian</surname><given-names>S.P.</given-names></name>
<name><surname>Pepin</surname><given-names>E.</given-names></name>
<name><surname>Zydney</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Purification of a conjugated polysaccharide vaccine using tangential flow diafiltration</article-title><source>Biotech. Bioeng.</source><year>2018</year><volume>116</volume><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1002/bit.26867</pub-id><pub-id pub-id-type="pmid">30450582</pub-id>
</element-citation></ref><ref id="B52-vaccines-13-00167"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emami</surname><given-names>P.</given-names></name>
<name><surname>Motevalian</surname><given-names>S.P.</given-names></name>
<name><surname>Pepin</surname><given-names>E.</given-names></name>
<name><surname>Zydney</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Impact of module geometry on the ultrafiltration behavior of capsular polysaccharides for vaccines</article-title><source>J. Membr. Sci.</source><year>2018</year><volume>561</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.memsci.2018.05.024</pub-id></element-citation></ref><ref id="B53-vaccines-13-00167"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadidi</surname><given-names>M.</given-names></name>
<name><surname>Zydney</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Fouling behaviour of zwitterionic membranes: Impact of electrostatic and hydrophobic interactions</article-title><source>J. Membr. Sci.</source><year>2014</year><volume>452</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.memsci.2013.09.062</pub-id></element-citation></ref><ref id="B54-vaccines-13-00167"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hitri</surname><given-names>K.</given-names></name>
<name><surname>Kuttel</surname><given-names>M.M.</given-names></name>
<name><surname>De Benedetto</surname><given-names>G.</given-names></name>
<name><surname>Lockyer</surname><given-names>K.</given-names></name>
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Hansal</surname><given-names>P.</given-names></name>
<name><surname>Rudd</surname><given-names>T.R.</given-names></name>
<name><surname>Beamish</surname><given-names>E.</given-names></name>
<name><surname>Rijpkema</surname><given-names>S.</given-names></name>
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">O</italic>-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3866</fpage><lpage>3875</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.05.050</pub-id><pub-id pub-id-type="pmid">31160100</pub-id>
</element-citation></ref><ref id="B55-vaccines-13-00167"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hlozek</surname><given-names>J.</given-names></name>
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
<name><surname>Kuttel</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Modeling the conformations of <italic toggle="yes">Neisseria meningitidis</italic> serogroup a CPS and a carba-analogue: Implications for vaccine development</article-title><source>Carbohydr. Res.</source><year>2019</year><volume>486</volume><fpage>10738</fpage><pub-id pub-id-type="doi">10.1016/j.carres.2019.107838</pub-id><pub-id pub-id-type="pmid">31654945</pub-id>
</element-citation></ref><ref id="B56-vaccines-13-00167"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michon</surname><given-names>F.</given-names></name>
<name><surname>Huang</surname><given-names>C.-H.</given-names></name>
<name><surname>Farley</surname><given-names>E.K.</given-names></name>
<name><surname>Hronowski</surname><given-names>L.</given-names></name>
<name><surname>Di</surname><given-names>J.</given-names></name>
<name><surname>Fusco</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: Effect of <italic toggle="yes">O</italic>-acetylation on the nature of the protective epitope</article-title><source>Dev. Biol.</source><year>2000</year><volume>103</volume><fpage>51</fpage><lpage>160</lpage></element-citation></ref><ref id="B57-vaccines-13-00167"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>De Ricco</surname><given-names>R.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
</person-group><article-title>Role of <italic toggle="yes">O</italic>-acetylation in the immunogenicity of bacterial polysaccharide vaccines</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>1340</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23061340</pub-id><pub-id pub-id-type="pmid">29865239</pub-id>
</element-citation></ref><ref id="B58-vaccines-13-00167"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kale</surname><given-names>S.</given-names></name>
<name><surname>Phugare</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>P.</given-names></name>
<name><surname>Goel</surname><given-names>S.K.</given-names></name>
<name><surname>Gairola</surname><given-names>S.</given-names></name>
</person-group><article-title>Method development and validation of unbound saccharide content (serogroup A, C, Y, W, X) in novel pentavalent meningococcal polysaccharide conjugate vaccine with two different carrier proteins</article-title><source>J. Pharm. Biomed. Anal.</source><year>2023</year><volume>236</volume><elocation-id>115679</elocation-id><pub-id pub-id-type="doi">10.1016/j.jpba.2023.115679</pub-id><pub-id pub-id-type="pmid">37660546</pub-id>
</element-citation></ref><ref id="B59-vaccines-13-00167"><label>59.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rao</surname><given-names>V.S.R.</given-names></name>
<name><surname>Qasba</surname><given-names>P.K.</given-names></name>
<name><surname>Balaji</surname><given-names>P.V.</given-names></name>
<name><surname>Chandrasekaran</surname><given-names>R.</given-names></name>
</person-group><source>Conformation of Carbohydrates</source><edition>1st ed.</edition><publisher-name>Harwood Academic Publishers</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>1998</year></element-citation></ref><ref id="B60-vaccines-13-00167"><label>60.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Chaplin</surname><given-names>M.</given-names></name>
</person-group><article-title>Polysaccharide hydration. Water Structure and Science</article-title><comment>Available online: <ext-link xlink:href="https://water.lsbu.ac.uk/water/" ext-link-type="uri">https://water.lsbu.ac.uk/water/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-29">(accessed on 29 January 2025)</date-in-citation></element-citation></ref><ref id="B61-vaccines-13-00167"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnsen</surname><given-names>E.</given-names></name>
<name><surname>Brandtzaeg</surname><given-names>O.K.</given-names></name>
<name><surname>Vehus</surname><given-names>T.</given-names></name>
<name><surname>Roberg-Larsen</surname><given-names>H.</given-names></name>
<name><surname>Bogoeva</surname><given-names>V.</given-names></name>
<name><surname>Ademi</surname><given-names>O.</given-names></name>
<name><surname>Hildahl</surname><given-names>J.</given-names></name>
<name><surname>Lundanes</surname><given-names>E.</given-names></name>
<name><surname>Wilson</surname><given-names>S.R.</given-names></name>
</person-group><article-title>A critical evaluation of Amicon Ultra centrifuge filters for separating proteins, drugs and nanoparticles in biosamples</article-title><source>J. Pharm. Biomed. Anal.</source><year>2016</year><volume>120</volume><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2015.12.010</pub-id><pub-id pub-id-type="pmid">26719981</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00167-f001"><label>Figure 1</label><caption><p><bold>SEC chromatograms of the purified MenC fractions after depolymerization and desalting.</bold> MenC full-length PS (blue) was subjected to hydrolysis for 15 (red), 30 (green), and 90 min (purple). The injections were performed using a Tosoh TSK PW<sub>XL</sub> guard column in series with Tosoh TSKgel G6000 + 5000 PW<sub>XL</sub> HPLC columns with PBS &#x0201c;A&#x0201d; as the mobile phase. The void volume (V<sub>0</sub>) and total column volume (V<sub>t</sub>) were determined using salmon DNA (Sigma Aldrich) and tyrosine (Sigma Aldrich), measured at 24.6 and 49.9 min, respectively. The absorbance of the polysaccharides was measured at 214 nm (indicated on the y-axis), which detects their amine, carbonyl, and carboxyl groups. Peak elution times are displayed for each.</p></caption><graphic xlink:href="vaccines-13-00167-g001" position="float"/></fig><fig position="float" id="vaccines-13-00167-f002"><label>Figure 2</label><caption><p><bold>Size characterization of ultrafiltration membranes using meningococcal group C polysaccharides</bold>. (<bold>a</bold>) Recovery of sized MenC polysaccharides from Microcon-10, -30 kDa, and -100 kDa ultrafiltration membranes. Percent filtrate recovery values are listed on each bar. For two samples run with the 10 kDa membrane, n.d., no data were recovered. (<bold>b</bold>) Effect of PS diameter on PS recovery. Data points are from purified PS samples: full-length (blue), 15 min (red), 30 min (green), and 90 min (purple) hydrolysates. The recovery of PS from ultrafiltration membranes with the measured diameters from this study and NMWCO values: 10 kDa (squares), 30 kDa (circles), and 100 kDa (diamonds) membranes are shown.</p></caption><graphic xlink:href="vaccines-13-00167-g002" position="float"/></fig><table-wrap position="float" id="vaccines-13-00167-t001"><object-id pub-id-type="pii">vaccines-13-00167-t001_Table 1</object-id><label>Table 1</label><caption><p>Size characteristics of meningococcal C polysaccharide fragments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mw (g/mol)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Polydispersity (Mw/Mn)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hydrodynamic <break/>RMS Radius Moments <break/>(Rn, nm) </th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<italic toggle="yes">MenC polysaccharides in ultrafiltration membrane characterization</italic>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MenC (FL) 0 min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">287,300 (&#x000b1;8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.03 (&#x000b1;11%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.5 (&#x000b1;4%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MenC 15 min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130,000 (&#x000b1;5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 (&#x000b1;8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.3 (&#x000b1;3%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MenC 30 min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52,860 (&#x000b1;4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07 (&#x000b1;20%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.3 (&#x000b1;8%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MenC 90 min</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22,190 (&#x000b1;28%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.51 (&#x000b1;52%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.7 (&#x000b1;22%)</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<italic toggle="yes">Low MW control used in free saccharide assays *</italic>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MenC control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24,100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.4</td></tr></tbody></table><table-wrap-foot><fn><p>* Lockyer et al., 2020 [<xref rid="B37-vaccines-13-00167" ref-type="bibr">37</xref>]. The values in parentheses represent the instrument error as reported by the Astra version 6.1 software.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00167-t002"><object-id pub-id-type="pii">vaccines-13-00167-t002_Table 2</object-id><label>Table 2</label><caption><p>Percentage of free saccharide following ultrafiltration of MenC-CRM<sub>197</sub> conjugates at varying ionic strengths.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diluent</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Free Saccharide (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.5 (%CV 8.7)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 mM Bis-Tris, pH 7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.5 (%CV 3.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 mM KCl in <break/>10 mM Bis-Tris, pH 7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.8 (%CV 4.1)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 mM KCl in <break/>10 mM Bis-Tris, pH 7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.3 (%CV 8.6)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">250 mM KCl in<break/>10 mM Bis-Tris, pH 7</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.2 (%CV 0.7)</td></tr></tbody></table><table-wrap-foot><fn><p>The %CV values of the free saccharide were determined from three replicate preparations.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00167-t003"><object-id pub-id-type="pii">vaccines-13-00167-t003_Table 3</object-id><label>Table 3</label><caption><p>Comparison of free saccharide methods, ultrafiltration (UF), detergent precipitation (DOC), and hydrophobic beads (SPE) for MenC-CRM<sub>197</sub> conjugates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Method</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Replicate</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Free Saccharide (%)&#x02014;DAY 1</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Free Saccharide (%)&#x02014;DAY 2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Free Saccharide (%)&#x02014;Combined</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">%CV</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Free</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Free</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">UF</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6.1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6.5</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.65</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.3</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.7</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10.0</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">8.4</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low MW MenC control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DOC</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.4</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.7</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low MW MenC control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SPE</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">14.5</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">14.8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.1</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">11.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.0</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">18.6</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15.1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low MW MenC control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00167-t004"><object-id pub-id-type="pii">vaccines-13-00167-t004_Table 4</object-id><label>Table 4</label><caption><p>Comparison of free saccharide methods, ultrafiltration (UF), and detergent precipitation (DOC) for MenA-CRM<sub>197</sub> conjugates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Method</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Replicate</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Free Saccharide (%)&#x02014;DAY 1</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Free Saccharide (%)&#x02014;DAY 2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Free Saccharide (%)&#x02014;Combined</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">%CV</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Free</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Free</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">UF</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.0</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.9</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low MW MenA control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DOC</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.7</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.3</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low MW MenA control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00167-t005"><object-id pub-id-type="pii">vaccines-13-00167-t005_Table 5</object-id><label>Table 5</label><caption><p>Comparison of free saccharide methods, ultrafiltration (UF), and detergent precipitation (DOC) for MenW-CRM<sub>197</sub> conjugates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Method</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sample</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Replicate</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Free Saccharide (%)&#x02014;DAY 1</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Free Saccharide (%)&#x02014;DAY 2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Free Saccharide (%)&#x02014;Combined</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">% CV</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Free</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Free</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">UF</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.7</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.7</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.9</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>MW MenW control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DOC</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.0</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.6</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">8.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.4</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">13.8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">11.0</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low <break/>MW MenW control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap></floats-group></article>